Resumen
INTRODUCCIÓN:La esclerosis múltiple es una enfermedad neuroinflamatoria, crónica, degenerativa e incurable, asociada a pérdida neuronal, grados crecientes de discapacidad y deterioro cognoscitivo. Su manejo conlleva grandes costos para los sistemas de salud y la sociedad en general.
OBJETIVO:Evaluar la eficacia y la seguridad del uso del rituximab en el manejo de la esclerosis múltiple.
MATERIALES Y MÉTODOS:Revisión de la literatura y evaluación de la tecnología en salud tipo mini-HTA en red colaborativa con el Comité de Esclerosis Múltiple de la Asociación Colombiana de Neurología y el Instituto Global de Excelencia Clínica.
RESULTADOS:Se identificaron 27 referencias de texto completo para el análisis de la seguridad y la eficacia del rituximab en el manejo de la esclerosis múltiple. Se utilizaron análisis de costos, indicadores epidemiológicos y estudios pivótales de rituximab.
CONCLUSIÓN:La evidencia analizada confirma que la terapia con rituximab es efectiva y segura en el manejo de las formas de esclerosis múltiple remitente-recurrente (EMRR) y esclerosis múltiple primaria-progresiva (EMPP), con menor tasa de eventos adversos y tasas de interrupción o abandono del tratamiento más bajas que otras terapias modificadoras de la enfermedad (TME).
Citas
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269-85. doi: 10.1016/S1474-4422(18)30443-5.
Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13(9):936-48. doi: 10.1016/S1474-4422(14)70093-6.
Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS One. 2018;13(5):e0197415. https://doi.org/10.1371/journal.pone.019.
Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017;13(9):567-72. https://doi.org/10.1038/nrneurol.2017.10.
Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019;19(1):5-20. doi: 10.1136/practneurol-2018-001899.
D'Amico E, Zanghi A, Chisari CG, Fermo S Lo, Toscano S, Arena S, et al. Effectiveness and safety of rituximab in demyelinating diseases spectrum: An Italian experience. Mult Scler Relat Disord. 2019;27:324-26. doi: 10.1016/j.msard.2018.09.041.
Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Mult Scler. 2020;26(2):137-52. doi: 10.1177/1352458519858604.
Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34(4):919-39. doi: 10.1016/j.ncl.2016.06.016.
Multiple Sclerosis International Federation (MSIF). Atlas of multiple sclerosis 2013. Mapping multiple sclerosis around the world [Internet]. MS International Federation. 2013 [citadp 2019 Oct 7]. p. 28. Disponible en: Disponible en: https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/atlas/
Garcia Merino A, Ramon Ara Callizo J, Fernandez Fernandez O, Landete Pascual L, Moral Torres E, Rodriguez-Antiguedad Zarrantz A. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia. 2017;32(2):113-9. https://doi.org/10.1016/j.nrl.2016.02.02.
Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22(2):117-39.
Jiménez-Pérez CE, Zarco-Montero LA, Castañeda-Cardona C, Otálora Esteban M, Martínez A, Rosselli D. Estado actual de la esclerosis múltiple en Colombia. Acta Neurol Colomb. 2015;31:385-90.
Toro J, Cardenas S, Fernando Martinez C, Urrutia J, Diaz C. Multiple sclerosis in Colombia and other Latin American countries. Mult Scler Relat Disord. 2013;2(2):80-89. https://doi.org/10.1016/j.msard.2012.09.001.
Gyllensten H, Wiberg M, Alexanderson K, Norlund A, Friberg E, Hillert J, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2018;19(3):435-46. https://doi.org/10.1007/s10198-017-0894-6.
Svendsen B, Grytten N, Bo L, Aarseth H, Smedal T, Myhr KM. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ. 2018;19(9):1243-57. https://doi.org/10.1007/s10198-018-97.
World Health Organization. Health technology assessment [Internet]. World Health Organization - WHO. [citado 2019 Jul 17]. Disponible en: Disponible en: http://www.who.int/health-technology-assessment/en/
Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a irst demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904. doi: 10.1056/NEJM200009283431301.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a irst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397. doi: 10.1016/S0140-6736(07)61194-5.
National Institute for Health and Care Excellence (NICE). Beta interferons and glatiramer acetate for treating multiple sclerosis. Guidance TA527 NICE [Internet]. 2018 [citado 2019 Jun 27]. p. 1-29. Disponible en: Disponible en: https://www.nice.org.uk/guidance/ta527
Alcalá C, Gascón F, Pérez-Miralles F, Domínguez JA, Gil-Perotín S, Casanova B. Treatment with alemtuzumab or ritux-imab after ingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. J Neurol. 2019;266(3):726-34. doi: 10.1007/s00415-019-09195-2.
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, ingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020;7(9):1466-76. doi: 10.1002/acn3.51111.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-34. doi: 10.1056/NEJMoa1601277.
Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, et al. Natalizumab, rituximab and ingoli-mod as escalation therapy in multiple sclerosis. Eur J Neurol. 2019;26(8):1060-7. https://doi.org/10.1111/ene.13936.
AAN. Academia Americana de Neurología. Cambio de terapias modiicadoras de la enfermedad (TME) para esclerosis múltiple [Internet]. 2018 [citado 2019 Aug 7]. p. 3. Disponible en: Disponible en: https://www.aan.com/Guidelines/Home/GetGuideline-Content/949
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88. https://doi.org/10.1056/NEJMoa0706383.
Berntsson SG, Kristoffersson A, Bostrom I, Feresiadou A, Burman J, Landtblom AM. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor? Acta Neurol Scand. 2018;138(4):327-31. https://doi.org/10.1111/ane.12963.
Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320-7. https://doi.org/10.1001/jamaneu-rol.2017.4.
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, et al. Rituximab versus ingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950-8. https://doi.org/10.1002/ana.24651.
Langer-Gould A, Piehl F, Smith J, Frisell T. Mortality rates in large US and Swedish rituximab-treated multiple sclerosis cohorts. ECTRIMS Online Library. 2018. p. 35-6. Available in: https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/231830/annette.langer-gould.mortality.rates.in.large.us.and.swedish.rituximab-treated.html
Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 2014;3(2):227-36. https://doi.org/10.1016/j.msard.2013.09.
Bar-Or A, Calabresi PAJ, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395-400. https://doi.org/10.1002/ana.21363.
Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460- 71. https://doi.org/10.1002/ana.21867.
Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and eficacy. Neurology. 2016;87(20):2074-81. https://doi.org/10.1212/WNL.0000000000.
Xie Q, Li X, Sun J, Yuan B, Li Y, Wang L, et al. A meta- analysis to determine the eficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis. Exp Ther Med. 2017;13(6):3061-6. https://doi.org/10.3892/etm.2017.4298.
Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2019;25(6):828-36. https://doi.org/10.1177/1352458518772748.
Hu Y, Nie H, Yu H-H, Qin C, Wu L-J, Tang Z-P, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019;18(5):542-8. https://doi.org/10.1016/j.autrev.2019.03.
Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Rituximab: eicacia, efectividad y seguridad en el tratamiento de la esclerosis múltiple. Rev Neurol. 2018;66:25-32.
Rommer PS, Dorner T, Freivogel K, Haas J, Kieseier BC, Kumpfel T, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: Experience from a national online registry (GRAID). J Neuroimmune Pharmacol. 2016;11(1):1-8. https://doi.org/10.1007/s11481-015-9646-5.
Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM. Safety and eficacy of rituximab in multiple sclerosis: A retrospective observational study. J Immunol Res. 2018;2018:9084759. https://doi.org/10.1155/2018/9084759.
Alcala C, Gascon F, Perez-Miralles F, Gil-Perotin S, Navarre A, Bosca I, et al. Eficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265(7):1690-7. https://doi.org/10.1007/s00415-018-8899.
Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020;94(18):e1939-e1949. doi: 10.1212/WNL.0000000000009374.
Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer- Gould A. Rituximab, MS, and pregnancy. Neurol Neuro- immunol Neuroinflammation. 2020;7(4). doi: 10.1212/NXI.0000000000000734.
Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018;13(1):e0190425. doi: 10.1371/journal.pone.0190425.
Tian X, Chen C, Ma L, Wei R, Li M, Wang X, et al. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2020;347:577317. doi: 10.1016/j.jneuroim.2020.577317.
Leonidou E, Pantzaris M, Kleopa KA, Loizidou MA, Kyriakides T, Christou YP. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus. Postgrad Med. 2019;131(7):486-89. doi: 10.1080/00325481.2019.1649975.
Collongues N, de Seze J. An update on the evidence for the eficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016;9(3):180-8. doi: 10.1177/1756285616632653.
Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol. 2019;76(3):274-81. doi: 10.1001/jamaneurol.2018.4239.
Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One . 2013;8(7):e66308. doi: 10.1371/journal.pone.0066308.
Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883-91. doi: 10.1136/jim-2016-000339.
Ministerio de Salud y Protección Social; Dirección de Medicamentos y Tecnologías. Abecé de medicamentos con UNIRS, reglamentados por la Resolución 1885 de 2018 [Internet]. 2019 [citado 2019 Ago 17]. Disponible en: Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/abc-medicamentos-con-unirs.pdf
Siddiqui MK, Singh B, Attri S, Veraart C, Harty G, Wong SL. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review. Curr Med Res Opin. 2020;36(5):809-26. doi: 10.1080/03007995.2020.1739009.
Bellinvia A, Prestipino E, Portaccio E, Razzolini L, Fonderico M, Fratangelo R, et al. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurol Sci. 2020;41(10):2939-45. doi: 10.1007/s10072-020-04434-1.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gun-narsson M, et al. Infection risks among patients with multiple sclerosis treated with ingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-91. doi: 10.1001/jamaneurol.2019.3365.
Hellgren J, Risedal A, Kállén K. Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand. 2020;141(6):491-99. doi: 10.1111/ane.13225.
Matthew T, John SK, Kamath V, Murgod U, Thomas K, Baptist AA, et al. Eficacy and safety of rituximab in multiple sclerosis: Experience from a developing country. Mult Scler Relat Disord. 2020;43:102210. doi: 10.1016/j.msard.2020.102210.
Evertsson B, Hoyt T, Christensen A, Nimer F Al, Foley J, Piehl F. A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocreli-zumab vs low dose of rituximab in multiple sclerosis. Mult Scler J - Exp Transl Clin. 2020;6(4):2055217320964505. doi: 10.1177/2055217320964505.
Xiao H, Zeng W, Li L, Li L, Cui Y, Wang J, et al. Retrospective observation of low-dose rituximab treatment in chinese patients with neuromyelitis optica spectrum disorders in a real-world setting. Front Neurol. 2020;11:642. doi: 10.3389/fneur.2020.00642.
Alldredge B, Jordan A, Imitola J, Racke MK. Safety and eficacy of rituximab: Experience of a single multiple sclerosis center. Clin Neuropharmacol. 2018;41(2):56-59. doi: 10.1097/WNF.0000000000000268.
Cubillos L, Alfonso E. Análisis descriptivo preliminar de los recobros en el Sistema General de Seguridad Social en Salud. PARS 2007 [Internet]. MSPS. 2007 [citado 2021 Jun 17]. Disponible en: Disponible en: https://www.minsalud.gov.co/salud/Documents/AnalisisDescriptivoPreliminardelosRecobros.pdf
Rodriguez A, Osorio SA. Evaluación económica de alem-tuzumab comparado con natalizumab en el tratamiento de esclerosis múltiple remitente recurrente en Colombia [Internet]. 2020 [citado 2021 Jun 17]. Disponible en: Disponible en: http://repository.javeriana.edu.co/handle/10554/51870
Esmaeili S, Abbasi MH, Abolmaali M, Mojtahed M, Alavi SNR, Soleimani S, et al. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. BMC Neurol. 2021;21(1):183. doi: 10.1186/s12883-021-02218-4.
Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitaliza-tion and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:102472. doi: 10.1016/j.msard.2020.102472.
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. COVID-19 in patients with multiple sclerosis: Associations with disease-modifying therapies. CNS Drugs. 2021;35(3):317-30. doi: 10.1007/s40263-021-00804-1.
Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020;127:104378. doi: 10.1016/j.jcv2020.104378.
Maarouf A, Rico A, Boutiere C, Perriguey M, Demortiere S, Pelletier J, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflammation. 2020;7(5):doi: 10.1212/NXI.0000000000000825.
Ricardo A, Carnero Contentti E, Anabel SB, Adrian LP, Orlando G, Fernando H, et al. Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A Latin American survey. Mult Scler Relat Disord. 2020;44:102310. doi: 10.1016/j.msard.2020.102310.
Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. Nat Rev Neurol. 2020;16(9):493-505. doi: 10.1038/s41582-020-0385-8.
Multiple Sclerosis International Federation. The coronavi-rus and MS - updated global advice [Internet]. MSIF. 2021 [citado 2021 Jun 30]. Disponible en: Disponible en: https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/
Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580-6. doi: 10.4049/jimmunol.1400118.
Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler. 2020;26(10):1261-4. doi: 10.1177/1352458520943791.
Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol. 2021;356:577599. doi: 10.1016/j.jneuroim.2021.577599.
Ciotti JR, Valtcheva M V, Cross AH. Effects of MS disease- modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020;45:102439. doi: 10.1016/j.msard.2020.102439.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.